US 11,939,291 B2
GRP94 selective inhibitors and uses thereof
Sanket Jaiprakash Mishra, Mishawaka, IN (US); Brian S. J. Blagg, Niles, MI (US); and Chad Anthony Dickey, Tampa, FL (US)
Assigned to University of Kansas, Lawrence, KS (US); and University of South Florida, Tampa, FL (US)
Filed by University of Kansas, Lawrence, KS (US); and University of South Florida, Tampa, FL (US)
Filed on Apr. 9, 2021, as Appl. No. 17/226,359.
Application 17/226,359 is a continuation of application No. 16/346,039, granted, now 10,975,030, previously published as PCT/US2017/059362, filed on Oct. 31, 2017.
Claims priority of provisional application 62/415,078, filed on Oct. 31, 2016.
Prior Publication US 2022/0024869 A1, Jan. 27, 2022
Int. Cl. C07D 207/325 (2006.01); A61P 27/06 (2006.01); A61P 35/00 (2006.01); C07C 13/18 (2006.01); C07D 213/62 (2006.01); C07D 401/06 (2006.01)
CPC C07D 207/325 (2013.01) [A61P 27/06 (2018.01); A61P 35/00 (2018.01); C07C 13/18 (2013.01); C07D 213/62 (2013.01); C07D 401/06 (2013.01)] 20 Claims
 
1. A compound according to Formula III

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt and/or solvate thereof, wherein
X21 is N or C—R35;
X22 is N or C—R36;
X23 is N or C—R37;
W2 is C(R40)(R41), O, or S;
R31 is alkyl, cycloalkyl, aryl, heterocyclyl, or X24—R42;
R32, R33, R34, R35, R36, R37, R38, R39, R40, and R41 are each independently H, OH, alkyl, alkoxy, aryloxy, heteroaryloxy, amino, halo, trifluoromethyl, or cyano;
X24 is O, S, or NH;
R42 is alkyl, cycloalkyl, aryl, or heterocyclyl;
Z2 is O, S, or NH; and
m is 0 or 1.